Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | PTPRC | P08575 | 1/20 | 0.51 |
| ▸ | PTPRF | P10586 | 1/20 | 0.51 |
| ▸ | CDC25B | P30305 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12365135 | 0.85 | EGFR (0.49) | OPRD1OPRK1KCNH2PTPN1PTPRC | |
| SCHEMBL12365142 | 0.84 | PTGS2 (0.46) | OPRD1OPRK1KCNH2PTPN1PTPRC | |
| SCHEMBL6491384 | 0.83 | OPRD1 (0.51) | OPRD1OPRK1KCNH2EGFRTSHR | |
| SCHEMBL6492765 | 0.82 | OPRD1 (0.39) | OPRD1OPRK1KCNH2TSHR | |
| SCHEMBL12365102 | 0.81 | NPC1 (0.47) | TSHRMEN1KMT2AMAPTKDM4E | |
| SCHEMBL12365115 | 0.81 | RAB9A (0.47) | OPRD1OPRK1KCNH2PTPN1PTPRC | |
| SCHEMBL12365112 | 0.80 | SLC6A3 (0.41) | TSHRMEN1KMT2AMAPTKDM4E | |
| SCHEMBL12389592 | 0.80 | CA1 (0.48) | OPRD1MEN1KMT2AMAPTSETD7 | |
| SCHEMBL12365101 | 0.80 | PTGS1 (0.43) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL12389869 | 0.78 | RAB9A (0.38) | OPRD1OPRK1KCNH2PTPN1PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962938-B2 | Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040132693-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2004-07-08 | — | — | US | disclosed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | disclosed |
| EP-1373199-A4 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1373199-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | Bristol-Myers Squibb Pharma Company (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030087882-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-08 | — | — | US | disclosed |
| WO-2002074738-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087882-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | ADAM17, ADAM9, TIMP3 | OPRD1 1752/4885OPRK1 2331/4885KCNH2 4295/4885 |
| US-20040132693-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | ADAM17, ADAM9, TIMP3 | OPRD1 1752/4885OPRK1 2331/4885KCNH2 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.